Trial Profile
Phase Ib Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Cyclophosphamide (Primary) ; Interleukin-2 (Primary) ; Ipilimumab (Primary) ; T cell replacement therapy (Primary)
- Indications Uveal melanoma
- Focus Adverse reactions; First in man
- 31 Jul 2023 Planned End Date changed from 1 Jul 2023 to 31 Jul 2025.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 18 Jan 2023 Planned End Date changed from 1 Feb 2023 to 1 Jul 2023.